An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02325219 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: CNTO 1959 50 mg
DRUG: CTNO 1959 100 mg
DRUG: Placebo 50 mg
DRUG: Placebo 100 mg

Sponsor

Janssen Pharmaceutical K.K.